On December 29, 2025 Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin technology platform, reported the termination of their collaboration agreement signed in May 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended to pool their tumor targeting and identification technologies to discover and develop new radiotheranostic agents that are more precise and effective against resistant and metastatic cancers.
The end of this partnership follows a standard prioritization process inherent in advanced research programs. OPM is actively pursuing its innovation strategy in precision medicine and continues to develop its portfolio of assets through its three technology platforms:
Nanocyclix, dedicated to the design and selection of next-generation kinase inhibitors;
OncoSNIPER, for the selection of therapeutic targets using artificial intelligence;
PROMETHE, to design and select radiolabeled biological molecules for systemic radiotherapy.
The COMETE program (moleCular radiOtherapy for METastatic Colorectal and gastric cancErs), which aims to develop a portfolio of radiotheranostic molecules for the treatment of advanced digestive cancers, is continuing. This project, led by OPM, the cancer center (CGFL), and the Institute of Molecular Chemistry at the University of Burgundy (ICMUB, UMR CNRS 6302), all based in Dijon, aims to develop a radiotheranostic candidate through preclinical dosimetry studies. OPM will evaluate other promising vectorization technologies and new target selection work is progressing.
Navigo Proteins will continue the initiated program based on its Affilin and HEAD platform technologies as well as AI assisted de-novo protein design addressing gastric cancers with a strong focus on an accelerated pathway into early testing in human patients.
Philippe Genne, CEO of Oncodesign Precision Medicine, said: "We would like to warmly thank the Navigo team for the quality of the work accomplished. This collaboration has enabled us to explore relevant Affilin leads, even if our collaboration has not demonstrated the expected potential within the program timelines due to the challenges encountered with the first targets selected. Our relationship remains excellent and we continue to move forward with determination on our key programs, including COMETE, a major strategic initiative for OPM."
Henning Afflerbach, CEO of Navigo Proteins GmbH, added: "We have enjoyed working with OPM and maintain a strong mutual appreciation for their core expertise. While further strengthening our commitment to develop innovative radiotheranostics from discovery into the clinic for the benefit of human patients, we wish our partner OPM all the best for the future and remain open to discussions when new opportunities arise."
(Press release, Oncodesign, DEC 29, 2025, View Source [SID1234661647])